UTIs are the cause of roughly 8 million emergency room visits and 100,000 hospitalizations in the US each year, GSK said.

EAGLE-1 trial data shows gepotidacin’s potential in treating gonorrhoea, for which no new antibiotics have been approved ...

On March 25, the U.S. Food and Drug Administration (FDA) approved the first new antibiotic to treat UTIs in 30 years. The ...

Blujepa (gepotidacin) is a new antibiotic recently approved by the FDA for treating bladder infections caused by certain bacteria in women and girls ages 12 and older. Blujepa works differently ...

Blujepa (gepotidacin) is the first new antibiotic class approved in nearly 30 years, providing a crucial treatment option for drug-resistant urinary tract infections (UTIs). In clinical trials ...

Gepotidacin is an oral ... and vulvovaginal candidiasis. “The approval of Blujepa is a crucial milestone with uUTIs among the most common infections in women,” said Tony Wood, Chief Scientific ...

The pill, gepotidacin, will be sold under the brand name Blujepa and is expected to be available in the second half of 2025. Blujepa is approved to treat females 12 and older with uncomplicated ...

A new class of antibiotic has been found to be safe and effective in treating gonorrhea in late-stage trials, according to a ...

The decision to approve gepotidacin, which will be marketed as Blujepa, was supported by positive phase 3 data from the EAGLE-2 and EAGLE-3 trials, which demonstrated the antibiotic’s ...